2010 News Releases

December

• December 20, 2010
  Astellas and AstraZeneca agreed upon an extension of their existing license for Seroquel,to include Seroquel^Ⓡ extended release Tab in Japan
   
• December 10, 2010
  Astellas Pharma Inc. to Promote Employment of Differently Abled People
   
• December 8, 2010
  Astellas Pharma Enters Strategic Equity Deal with Cytori ; To Purchase $10 Million in Equity at $7.00 per Share (pdf 137KB)
   
• December 6, 2010
  Marketing Collaboration on Protopic^® Ointment for Treatment of Atopic Dermatitis in Japan
   
• December 3, 2010
  Astellas Pharma Inc. Announce Result of Changing Tomorrow DayTo Support Action in Worldwide Local Communities -Part6- (pdf146 KB)
   
• December 2, 2010
  OSI Pharmaceuticals, Inc. Exercises Option under Discovery and Translational Research Collaboration with AVEO (pdf 42KB)
   
• December 1, 2010
  Astellas Pharma Inc.: Marking 15th Anniversary Donation from Employee-Run Social Contribution Fund, "Flying Star Fund" (pdf 208KB)

November

• November 30, 2010
  Presentation Material of Press Conference on 29th November,2010 (pdf2.3 MB)
   
• November 24, 2010
  Astellas Pharma Inc. decided the new corporate name of Merged Production Subsidiary in Japan
   
• November 16, 2010
  Astellas Pharma Inc. and NITE: Search for Microorganisms Overseas in Accordance with the Principles of the Convention on Biological DiversityIndustry-Government Collaborative Research Program (pdf 187KB)
   
• November 16, 2010
  Astellas Pharma Inc. Announce Changing Tomorrow Day To Support Action in European Local Communities -Part5- (pdf 277 KB)
   
• November 1, 2010
  Astellas Pharma Inc.: FY2010-FY2014 Mid -Term Management Plan-Revised Target on Sales and Operating Income in Fiscal Year 2014-(pdf60 KB)
   
• November 1, 2010
  Astellas Pharma Inc.: Enter into Option Agreement with Alavita to Acquire Diannexin Assets

October

• October 28, 2010
  Astellas Pharma Inc.: Submits Application for Marketing Approval of Degarelix, an GnRH Antagonist for Prostate Cancer Treatment, in Japan
   
• October 28, 2010
  Astellas Pharma Inc. Files Lawsuit Against Nycomed For Patent Infringement In The United States
   
• October 27, 2010
  Astellas Obtained Approval for Vesicare OD in Japan (pdf 59KB)
   
• October 26, 2010
  Astellas to Merge the Production Subsidiaries in Japan (pdf48 KB)
   
• October 26, 2010
  Astellas Announce Changing Tomorrow Day To Support Action in Asian Local Communities - Part4 - (pdf260 KB)
   
• October 25, 2010
  Astellas Pharma Inc.: Donation of Six Wheelchair Vans by Employee-Run Social Contribution Fund "Flying Star Fund"
   
• October 19, 2010
  Astellas and ASKA Enter into License Agreement for AKP-002 (pdf 64KB)
   
• October 18, 2010
  Transfer of Manufacturing and Marketing Approval and Distribution Rights for the Anti-Allergic Drug "Intal^®" (pdf 86KB)
   
• October 18, 2010
  Astellas Pharma Inc. Announces Changing Tomorrow Day To Support Action in Local Communities -Part3- (pdf174 KB)
   
• October 5, 2010
  Micamlo^® Combination Tablets AP (new product) and Micardis^® Tablets 80 mg are launched on 7 October - Offer new options for effective antihypertensive treatment-(pdf137 KB)

September

• September 30, 2010
  Astellas and UMN Pharma enter into the definitive agreement for UMN Pharma's Cell Culture Based Influenza Vaccine Programs in Japan
   
• September 29, 2010
  Astellas Pharma Inc.: Submits Application for Marketing Approval of Darexaban (YM150), an Oral Direct Factor Xa Inhibitor, in Japan
   
• September 29, 2010
  Announcement of the NDA submission of Z-338 /YM443 for functional dyspepsia in Japan
   
• September 29, 2010
  Astellas Pharma US, Inc. Announces Changing Tomorrow Day To Support Action in Local Communities -Part2- (pdf132 KB)
   
• September 17, 2010
  Micamlo^® Combination Tablets AP Drug Price Listing (pdf108 KB)
   
• September 10, 2010
  Application for RECALBON^® Tablets 50mg/ Bonoteo^® Tablets 50mg, A Monthly Oral Osteoporosis Treatment in Japan
   
• September 8, 2010
  Astellas Announces Changing Tomorrow Day To Support Action in Local Communities-Part1- (pdf164 KB)
   
• September 8, 2010
  Donation of Ambulances on First-Aid Day (September 9)

August

• August 17, 2010
  Memorandum of Understandings for UMN Pharma's Cell Culture Based Influenza Vaccine Programs in Japan (pdf39 KB)

July

• July 28, 2010
  Astellas to Pay $295 Million to Extend License of Regeneron's VelocImmune^® Antibody Technology through 2023 (pdf 56KB)
   
• July 23, 2010
  Approval for Micamlo Combination Tablets AP Manufacturing and Distribution(pdf98 KB)
   
• July 8, 2010
  Contents of Stock Acquisition Rights(Stock Option Scheme as Stock-Linked Compensation Plan)(pdf34 KB)
   
• July 2, 2010
  Astellas Nominates President of OSI Pharmaceuticals, Inc. (pdf34 KB)

June

• June 28, 2010
  Astellas and Teva Reached a Settlement Agreement on VESIcare^® Patent Case
   
• June 28, 2010
  Astellas Announces Oral Presentation of SGLT2 Inhibitor Detailing Safety and Efficacy in Patients with Type 2 Diabetes at the American Diabetes Association Meeting(pdf40 KB)
   
• June 23, 2010
  Allotment of Stock Acquisition Rights (pdf76 KB)
   
• June 18, 2010
  Application for Mirabegron (YM178), a Treatment for OAB, in Japan (pdf42 KB)
   
• June 15, 2010
  Astellas' Brazilian Affiliate Initiates Business Operations(pdf38 KB)
   
• June 14, 2010
  Safety of telmisartan affirmed with an analysis of 50,000 patients(pdf38 KB)
   
• June 9, 2010
  Astellas Completes Acquisition of OSI Pharmaceuticals (pdf32 KB)
   
• June 8, 2010
  Astellas Announces Successful Completion of Tender Offer for Shares of OSI (pdf32 KB)
   
• June 3, 2010
  Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period (pdf42 KB)

May

• May 25, 2010
  Announcement of New Mid-Term Management Plan(pdf1.2 MB)
   
• May 24, 2010
  New Contracts Concerning telmisartan (Micardis^® Family) Have Been Concluded (pdf73 KB)
   
• May 18, 2010
  Expiration Date of OSI Offer Extended to June 2, 2010 (pdf40 KB)
   
• May 17, 2010
  Presentation Material for Acquisition of OSI Pharmaceuticals, Inc.(PDF343 KB)
   
• May 17, 2010
  Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
   
• May 12, 2010
  Astellas Announces Cancellation of Treasury Stock
   
• May 12, 2010
  Partial Amendments to the Articles of Incorporation (pdf 37KB)
   
• May 12, 2010
  Issuance of Stock Acquisition Rights for Stock Option Scheme as Stock-Linked Compensation Plan (pdf 62KB)

April

• April 28, 2010
  Astellas Pharma US, Inc. Announces Construction of New Corporate Headquarters
   
• April 28, 2010
  Astellas to Support Relief Efforts following China Chinghai Earthquake (pdf33 KB)
   
• April 26, 2010
  Astellas Nominates Directors(pdf34 KB)
   
• April 23, 2010
  Expiration Date of OSI Offer Extended to May 17, 2010 (pdf40 KB)
   
• April 16, 2010
  Medivation And Astellas Announce Publication in The LANCET of Positive Efficacy Data from Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients(pdf78 KB)
   
• April 12, 2010
  Astellas introduces 'Prograf^®' in India (pdf32 KB)
   
• April 1, 2010
  Teijin Pharma and Astellas Pharma Enter into Agreement for Marketing Rights of TMX-67 in China and Hong Kong (pdf54 KB)

March

• March 31, 2010
  Expiration Date of OSI Offer Extended to April 23, 2010(pdf61 KB)
   
• March 30, 2010
  Astellas Signs Confidentiality Agreement with OSI(pdf 51KB)
   
• March 23, 2010
  Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors(pdf49 KB)
   
• March 19, 2010
  Astellas Announces Expiration of HSR Waiting Period for OSI Tender Offer(pdf62 KB)
   
• March 17, 2010
  Astellas Announces Full Slate of Independent Director Nominees for Election at OSIPharmaceuticals'
  2010 Annual Stockholders Meeting（pdf65 KB）
   
• March 16, 2010
  Astellas Responds to OSI Pharmaceuticals' Rejection(pdf44 KB)
   
• March 3, 2010
  Astellas Pharma Inc. Commences Tender Offer to Acquire All Outstanding Shares of OSI Pharmaceuticals for $52 per Share in Cash Astellas Files Lawsuit Against OSI (pdf49 KB)
   
• March 1, 2010
  Astellas Pharma Inc. Offers to Acquire OSI Pharmaceuticals for $52.00 Per Share in Cash(pdf82 KB)
   
• March 1, 2010
  Astellas to Send Additional Relief Effort following Haiti Earthquake

February

• February 26, 2010
  Withdrawn application for approval of additional indication for type 2 diabetic incipient nephropathy for "Micardis^®Tablets", Angiotensin II receptor blocker
   
• February 24, 2010
  Entered into Global Partnership with Basilea for an Azole Antifungal Agent Isavuconazole

January

• January 19, 2010
  Astellas to Support Relief Efforts following Haiti Earthquake
   
• January 12, 2010
  Launch of Symbicort^® Turbuhaler^®for the Treatment of Adult Bronchial Asthma in Japan